217 related articles for article (PubMed ID: 23539442)
1. NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors.
Ice RJ; McLaughlin SL; Livengood RH; Culp MV; Eddy ER; Ivanov AV; Pugacheva EN
Cancer Res; 2013 May; 73(10):3168-80. PubMed ID: 23539442
[TBL] [Abstract][Full Text] [Related]
2. NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner.
Kozyreva VK; McLaughlin SL; Livengood RH; Calkins RA; Kelley LC; Rajulapati A; Ice RJ; Smolkin MB; Weed SA; Pugacheva EN
Mol Cancer Res; 2014 May; 12(5):681-93. PubMed ID: 24574519
[TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior.
Jones BC; Kelley LC; Loskutov YV; Marinak KM; Kozyreva VK; Smolkin MB; Pugacheva EN
Mol Cancer Res; 2017 Jun; 15(6):670-682. PubMed ID: 28235899
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells.
Zou Z; Yuan Z; Zhang Q; Long Z; Chen J; Tang Z; Zhu Y; Chen S; Xu J; Yan M; Wang J; Liu Q
Autophagy; 2012 Dec; 8(12):1798-810. PubMed ID: 23026799
[TBL] [Abstract][Full Text] [Related]
5. PRL-3 Promotes Ubiquitination and Degradation of AURKA and Colorectal Cancer Progression via Dephosphorylation of FZR1.
Zhang C; Qu L; Lian S; Meng L; Min L; Liu J; Song Q; Shen L; Shou C
Cancer Res; 2019 Mar; 79(5):928-940. PubMed ID: 30498084
[TBL] [Abstract][Full Text] [Related]
6. Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis.
Plotnikova OV; Nikonova AS; Loskutov YV; Kozyulina PY; Pugacheva EN; Golemis EA
Mol Biol Cell; 2012 Jul; 23(14):2658-70. PubMed ID: 22621899
[TBL] [Abstract][Full Text] [Related]
7. Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.
Singh MK; Izumchenko E; Klein-Szanto AJ; Egleston BL; Wolfson M; Golemis EA
Cancer Res; 2010 Nov; 70(21):8907-16. PubMed ID: 20940402
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.
Ratushny V; Pathak HB; Beeharry N; Tikhmyanova N; Xiao F; Li T; Litwin S; Connolly DC; Yen TJ; Weiner LM; Godwin AK; Golemis EA
Oncogene; 2012 Mar; 31(10):1217-27. PubMed ID: 21785464
[TBL] [Abstract][Full Text] [Related]
11. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
12. NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis.
McLaughlin SL; Ice RJ; Rajulapati A; Kozyulina PY; Livengood RH; Kozyreva VK; Loskutov YV; Culp MV; Weed SA; Ivanov AV; Pugacheva EN
Mol Cancer Res; 2014 Jan; 12(1):69-81. PubMed ID: 24202705
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.
Shagisultanova E; Gaponova AV; Gabbasov R; Nicolas E; Golemis EA
Gene; 2015 Aug; 567(1):1-11. PubMed ID: 25967390
[TBL] [Abstract][Full Text] [Related]
14. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.
Siggelkow W; Boehm D; Gebhard S; Battista M; Sicking I; Lebrecht A; Solbach C; Hellwig B; Rahnenführer J; Koelbl H; Gehrmann M; Marchan R; Cadenas C; Hengstler JG; Schmidt M
BMC Cancer; 2012 Nov; 12():562. PubMed ID: 23186136
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
16. NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer.
Loskutov YV; Kozyulina PY; Kozyreva VK; Ice RJ; Jones BC; Roston TJ; Smolkin MB; Ivanov AV; Wysolmerski RB; Pugacheva EN
Oncogene; 2015 Jul; 34(28):3662-75. PubMed ID: 25241893
[TBL] [Abstract][Full Text] [Related]
17. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
[TBL] [Abstract][Full Text] [Related]
18. Aurora A kinase (AURKA) in normal and pathological cell division.
Nikonova AS; Astsaturov I; Serebriiskii IG; Dunbrack RL; Golemis EA
Cell Mol Life Sci; 2013 Feb; 70(4):661-87. PubMed ID: 22864622
[TBL] [Abstract][Full Text] [Related]
19. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
20. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À
J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
